FDA General
<ѻýҕl>FDA Panel Split Over Inhaled Antipsychoticѻýҕl>
WASHINGTON -- An FDA advisory panel punted on the question of approval for an inhaled version of the antipsychotic drug loxapine (Adasuve) to treat agitation in bipolar and schizophrenic patients, despite the risk for respiratory side effects.
Dec 12, 2011
<ѻýҕl>AMA Adopts Policies on Circumcision, Gun Safetyѻýҕl>
The American Medical Association (AMA) House of Delegates has adopted a number of new policies at its interim meeting, including policies on male circumcision, physician discussion of gun safety, and a new medical coding system that will go into effect in 2013.
Nov 16, 2011
<ѻýҕl>Parkinson's Drug Doesn't Slow Disease Progress, FDA Staff Saysѻýҕl>
WASHINGTON -- Azilect (rasagiline), which is already approved to treat symptoms of Parkinson's disease, does not appear effective at slowing progression of the neurodegenerative disease, according to an FDA review.
Oct 14, 2011
<ѻýҕl>FDA Blocks Sale of Supplements for Parkinson's and Alzheimer'sѻýҕl>
WASHINGTON -- The FDA filed a permanent injunction against two Minnesota companies that distributed amino acid products marketed as treatments for Parkinson's disease, Alzheimer's disease, and a number of other neurological disorders.
Sep 16, 2011
<ѻýҕl>Medicare to Keep Paying for Avastinѻýҕl>
WASHINGTON -- Medicare will continue to pay for bevacizumab (Avastin) when it's used to treat metastatic breast cancer, even if the FDA decides to remove that indication from the drug, a spokesman for the Centers for Medicare and Medicaid Services (CMS) said.
Jun 30, 2011
<ѻýҕl>AMA: House of Delegates Backs Individual Mandateѻýҕl>
CHICAGO -- The American Medical Association's House of Delegates has reaffirmed its support of individual responsibility -- including a requirement that most U.S. residents buy health insurance -- as the foundation of universal coverage.
Jun 20, 2011
<ѻýҕl>FDA Warns of High-Grade Prostate Ca Risk With BPH Drugsѻýҕl>
WASHINGTON -- The FDA has issued a warning of an increased risk of high-grade prostate cancer with the 5-alpha reductase inhibitors finasteride (Proscar) and dutasteride (Avodart), currently approved to treat benign prostatic hypertrophy.
Jun 09, 2011